Titanium Peroxide Composite for Targeted Radiotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiotherapy methods face challenges in effectively targeting cancer cells while minimizing side effects on normal tissues, as they require high radiation doses and frequencies, leading to limitations in treatment efficacy and patient burden.
Innovation Solution
A radiotherapeutic agent comprising a composite particle bound to a substrate containing titanium peroxide, which generates hydroxyl radicals upon radiation irradiation, allowing for targeted damage of cancer cells with reduced radiation doses and minimized side effects on normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high radiation doses are used to effectively kill cancer cells, then tumor killing efficacy is improved, but side effects on normal tissues increase
Solution Approach 1:
The patent applies local quality by using antibodies specifically targeted to cancer cell surface markers (such as EGFR, HER2, or other tumor-specific antigens) to conjugate with titanium peroxide particles. This ensures that the radiation-sensitive composite particles accumulate preferentially at the tumor site rather than being distributed throughout normal tissues. The specific antibody-target binding creates localized high concentration of hydroxyl radical generators at the tumor, improving cancer cell killing while minimizing normal tissue exposure to radiation-induced damage.
Solution Approach 2:
The patent uses an intermediary approach by introducing titanium peroxide particles as a mediator between radiation and cancer cells. These particles act as hydroxyl radical generators when exposed to radiation, converting physical radiation energy into chemical damage to cancer cells. The antibody-conjugated titanium peroxide composite particles serve as intermediaries that concentrate at the tumor site and amplify the radiation effect locally, allowing effective tumor treatment at lower overall radiation doses that reduce normal tissue side effects.
2Reliability
If high frequency radiation irradiation is used to treat deep tumors, then treatment efficacy is improved, but patient burden and side effects increase
Solution Approach 1:
The patent applies preliminary action by administering antibody-conjugated titanium peroxide composite particles to the patient before radiation therapy. The particles circulate in the bloodstream, accumulate at the tumor site through antibody-target binding, and position themselves optimally for radiation irradiation. This preliminary positioning ensures that when radiation is applied, the hydroxyl radical generators are already concentrated at the tumor, maximizing treatment efficacy for deep tumors while reducing the need for high-frequency irradiation and associated patient burden.
Solution Approach 2:
The patent uses composite materials by creating conjugates of antibodies and titanium peroxide particles to form composite particles. This composite structure combines the target-specific binding capability of antibodies with the radiation-enhancing hydroxyl radical generation ability of titanium peroxide. The composite particles accumulate at the tumor site and generate localized hydroxyl radicals upon radiation exposure, significantly enhancing treatment efficacy for deep-seated tumors while reducing the frequency and total dose of radiation needed, thereby decreasing patient burden.
3Reliability
If external radiation irradiation is used to target tumors, then cancer cell killing is improved, but normal tissue damage increases
Solution Approach 1:
The patent applies local quality by using antibodies specifically targeted to cancer cell surface markers (such as EGFR, HER2, or other tumor-specific antigens) to conjugate with titanium peroxide particles. This ensures that the radiation-sensitive composite particles accumulate preferentially at the tumor site rather than being distributed throughout normal tissues. The specific antibody-target binding creates localized high concentration of hydroxyl radical generators at the tumor, improving cancer cell killing while minimizing normal tissue exposure to radiation-induced damage.
Solution Approach 2:
The patent uses an intermediary approach by introducing titanium peroxide particles as a mediator between radiation and cancer cells. These particles act as hydroxyl radical generators when exposed to radiation, converting physical radiation energy into chemical damage to cancer cells. The antibody-conjugated titanium peroxide composite particles serve as intermediaries that concentrate at the tumor site and amplify the radiation effect locally, allowing effective tumor treatment at lower overall radiation doses that reduce normal tissue side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The radiotherapeutic agent effectively damages cancer cells by accumulating at the target site and generating hydroxyl radicals, reducing side effects on normal tissues and enhancing treatment efficacy with lower radiation doses, thus improving the effectiveness and tolerability of radiotherapy.
Implementation Method 1
a composite particle obtained by binding a molecule that specifically recognizes a target to a substrate particle containing titanium peroxide, in which the composite particle generates a hydroxyl radical through radiation irradiation
Implementation Method 2
titanium peroxide generates a hydroxyl radical at a high concentration when subjected to ultrasonic irradiation
Data Source
AI summary
Provided is a radiotherapeutic agent, including a composite particle, which is obtained by binding a molecule that specifically recognizes a target to a substrate particle including titanium peroxide, and which generates reactive oxygen through irradiation with a radiation. Further, because the radiotherapeutic agent contains the molecule that specifically recognizes a target, the radiotherapeutic agent has a function of accumulating in the target. The radiotherapeutic agent is capable of enhancing effects of radiotherapy, and is capable of reducing side effects on a living body to efficiently attack the target.